TrialPloS one2019

A prospective randomized trial on abacavir/lamivudine plus darunavir/ritonavir or raltegravir in HIV-positive drug-naïve patients with CD4<200 cells/uL (the PRADAR study).

Cristina Mussini et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.